论文部分内容阅读
目的:评价大剂量纳洛酮对急性重型颅脑损伤患者促醒的临床疗效。方法:选取2015年1月—2017年1月期间收治的急性重型颅脑损伤患者,采用格拉斯哥昏迷指数(Glasgow Coma Scale,简称GCS)评分后,选取其得分值为3~8分间的患者80例,将其随机分为观察组和对照组(每组40例);对照组患者根据其自身病情给予针对性的常规治疗,观察组患者在对照组治疗基础上加用大剂量纳洛酮注射液静脉注射治疗,比较两组患者用药后觉醒时间,以及治疗前后早期临床疗效和晚期的语言功能和运动功能的评分值。结果:观察组患者用药后觉醒时间明显优于对照组(P<0.05),治疗早期、晚期的临床疗效均明显优于对照组(P<0.05),病死率明显低于对照组(P<0.05)。结论:大剂量纳洛酮用于治疗急性重型颅脑损伤患者的临床疗效确切,患者觉醒快且病死率低。
Objective: To evaluate the clinical efficacy of high-dose naloxone in patients with acute severe craniocerebral injury. Methods: Patients with acute severe craniocerebral injury who were admitted between January 2015 and January 2017 were selected with Glasgow Coma Scale (GCS) scores, and their scores were between 3 and 8 80 cases were randomly divided into observation group and control group (40 cases in each group). Patients in the control group were given conventional treatment according to their own condition. Patients in the observation group were treated with high-dose naloxone Injection intravenous injection therapy, awakening time after treatment compared the two groups of patients, as well as early clinical efficacy and early post-treatment of language function and motor function score. Results: The awakening time in the observation group was significantly better than that in the control group (P <0.05). The clinical curative effect in the early and late stages of the treatment group was significantly better than that of the control group (P <0.05), and the mortality was significantly lower than that of the control group ). Conclusion: The high-dose naloxone is effective in the treatment of patients with acute severe craniocerebral injury. Patients are awake quickly and have low mortality.